Clindamycin - SkyePharma

Drug Profile

Clindamycin - SkyePharma

Alternative Names: Clindamycin HIT formulation - SkyePharma; Clindamycin Hyaluronan Induced Targeting formulation - SkyePharma; Hyclinda

Latest Information Update: 17 Oct 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Shire Pharmaceuticals Group; SkyePharma Inc
  • Developer Pacira Pharmaceuticals
  • Class Antibacterials; Lincosamides; Small molecules
  • Mechanism of Action Protein 50S ribosomal subunit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Acne

Most Recent Events

  • 31 Jul 2002 Hyclinda(TM) is available for licensing []
  • 07 Jun 2002 Phase-III clinical trials in Acne in United Kingdom (Topical)
  • 02 Oct 2001 No-Development-Reported for Acne in United Kingdom (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top